- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07365995
En fase III-studie av BNT324 versus Docetaxel ved metastatisk kastrasjonsresistent prostatakreft
En fase III, randomisert, åpen studie av BNT324 versus docetaxel med prednison/prednisolon ved metastatisk kastrasjonsresistent prostatakreft
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC.
The main goals of this study are:
- To find out if BNT324 helps participants live longer without their cancer getting worse (radiographic progression-free survival [rPFS]).
- To find out if BNT324 helps participants live longer overall (overall survival [OS]).
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The study consists of a screening period (up to 28 days), a treatment period with 21-day cycles, and an after-treatment period that includes a 30-day safety follow-up period and a long-term survival follow-up period.
Treatment continues until the cancer clearly gets worse (in scans, based on blinded independent central review [BICR] assessment or investigator's decision), side effects become unacceptable, the participant chooses to stop, or the study ends.
Participants are put into one of two groups in a 1:1 ratio, which means they will have an equal chance to be in either treatment group, i.e., BNT324 group, or docetaxel plus prednisone/prednisolone group (current SoC). An independent committee will help ensure participant safety, by regularly reviewing safety and early results.
For each participant, the treatment and follow-up periods are projected to be up to ~58 months.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: BioNTech clinical trials patient information
- Telefonnummer: +49 6131 9084
- E-post: patients@biontech.de
Studiesteder
-
-
-
Adelaide, Australia, 5000
- Rekruttering
- Cancer Research SA
-
Box Hill, Australia, 3128
- Rekruttering
- Box Hill Hospital
-
Heidelberg, Australia, 3084
- Rekruttering
- Austin Health
-
Southport, Australia, 4215
- Rekruttering
- Tasman Onco Research Pty Ltd
-
-
-
-
-
Brussels, Belgia, 1200
- Rekruttering
- Cliniques Universitaires Saint-Luc
-
Ghent, Belgia, 9000
- Rekruttering
- AZ Sint-Lucas Gent
-
-
-
-
-
Porto Alegre, Brasil, 90560-032
- Rekruttering
- Hospital Moinhos de Vento
-
-
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85715
- Rekruttering
- Del Sol Research Mgmt LLC
-
-
California
-
Santa Barbara, California, Forente stater, 93105
- Rekruttering
- Sansum Clinic
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Rekruttering
- Rocky Mountain Cancer Centers
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33901
- Rekruttering
- Florida Cancer Specialists- Fort Myers
-
St. Petersburg, Florida, Forente stater, 33701
- Rekruttering
- Florida Cancer Specialists- St. Petersburg
-
West Palm Beach, Florida, Forente stater, 33401
- Rekruttering
- Florida Cancer Specialists- West Palm Beach
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30318
- Rekruttering
- Piedmont Cancer Institute
-
-
Illinois
-
Niles, Illinois, Forente stater, 60714
- Rekruttering
- Illinois Cancer Specialists
-
Peoria, Illinois, Forente stater, 61615
- Rekruttering
- Illinois CancerCare PC
-
-
Maryland
-
Rockville, Maryland, Forente stater, 20850
- Rekruttering
- Maryland Oncology Hematology
-
-
New York
-
Albany, New York, Forente stater, 12206
- Rekruttering
- NYOH Albany Cancer Center
-
White Plains, New York, Forente stater, 10601
- Rekruttering
- White Plains Hospital
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45242
- Rekruttering
- Oncology/Hematology Care, Inc.
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Rekruttering
- START Carolinas
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Forente stater, 78731
- Rekruttering
- Texas Oncology South Austin
-
Houston, Texas, Forente stater, 77024
- Rekruttering
- Texas Oncology Gulf Coast
-
Tyler, Texas, Forente stater, 75702
- Rekruttering
- Texas Oncology, P.A. - Tyler
-
Wichita Falls, Texas, Forente stater, 76310
- Rekruttering
- Texas Oncology - West Texas
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Virginia Cancer Specialists PC
-
Norfolk, Virginia, Forente stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
-
-
-
-
Verona, Italia, 37124
- Rekruttering
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Beijing, Kina, 100142
- Rekruttering
- Beijing Cancer Hospital
-
Beijing, Kina, 100034
- Rekruttering
- Peking University First Hospital
-
Beijing, Kina, 100050
- Rekruttering
- Beijing Friendship Hospital, Capital Medical University
-
Changsha, Kina, 410005
- Rekruttering
- The First Affiliated Hospital of Hunan Normal University
-
Chengdu, Kina, 610041
- Rekruttering
- West China Hospital, Sichuan University
-
Chongqing, Kina, 400072
- Rekruttering
- The Second Affiliated Hospital of Chongqing Medical University
-
Chongqing, Kina, 400030
- Rekruttering
- Chongqing Univ. Cancer Hosp.
-
Fuzhou, Kina, 350001
- Rekruttering
- Fujian Medical University Union Hospital
-
Guangzhou, Kina, 510163
- Rekruttering
- The First Affiliated Hospital of Guangzhou Medical University
-
Hangzhou, Kina, 310022
- Rekruttering
- Zhejiang Cancer Hospital
-
Hangzhou, Kina, 310016
- Rekruttering
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
Hangzhou, Kina, 310014
- Rekruttering
- Zhejiang Prov. People's Hosp.
-
Hefei, Kina, 230601
- Rekruttering
- Second Hospital of Anhui Medical University
-
Nanchang, Kina, 330006
- Rekruttering
- The First Affiliated Hospital of Nanchang University
-
Nanjing, Kina, 210008
- Rekruttering
- Nanjing Drum Tower Hospital
-
Nantong, Kina, 226361
- Rekruttering
- Nantong Tumor Hospital
-
Ningbo, Kina, 315010
- Rekruttering
- The First Affiliated Hospital of Ningbo University
-
Shanghai, Kina, 200032
- Rekruttering
- Shanghai Cancer Center
-
Shanghai, Kina, 200072
- Rekruttering
- No. 10 People's Hospital of Shanghai
-
Shanghai, Kina, 200032
- Rekruttering
- Zhongshan Hospital
-
Wenzhou, Kina, 325000
- Rekruttering
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Kina, 430079
- Rekruttering
- Hubei Cancer Hospital
-
Wuhan, Kina, 420104
- Rekruttering
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhu, Kina, 241001
- Rekruttering
- Yijishan Hospital of Wannan Medical College
-
Yantai, Kina, 264000
- Rekruttering
- Yantai Yuhuangding Hospital
-
-
-
-
-
Krakow, Polen, 30-727
- Rekruttering
- Pratia MCM Krakow
-
Skorzewo, Polen, 60-185
- Rekruttering
- Szpital AidPort
-
Sosnowiec, Polen, 41-208
- Rekruttering
- Gyncentrum Szpital
-
Warsaw, Polen, 02-781
- Rekruttering
- National Research Institute of Oncology - National Research Institute (NIO-PIB)
-
-
-
-
-
Barcelona, Spania, 08036
- Rekruttering
- Hospital Clínic de Barcelona
-
Madrid, Spania, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre
-
Madrid, Spania, 28046
- Rekruttering
- Hospital Universitario La Paz
-
-
-
-
-
Cambridge, Storbritannia, CB2 0QQ
- Rekruttering
- Addenbrooke's Hospital
-
Cardiff, Storbritannia, CF14 2TL
- Rekruttering
- Velindre Cancer Centre
-
Leeds, Storbritannia, LS9 7TF
- Rekruttering
- St James's University Hospital
-
London, Storbritannia, SW3 6JJ
- Rekruttering
- Royal Marsden Hospital
-
London, Storbritannia, NW3 2QG
- Rekruttering
- Royal Free Hospital
-
Manchester, Storbritannia, M20 4BX
- Rekruttering
- The Christie Hospital
-
Newcastle upon Tyne, Storbritannia, NE7 7DN
- Rekruttering
- Freeman Hospital
-
Plymouth, Storbritannia, PL6 8DH
- Rekruttering
- Derriford Hospital
-
Southampton, Storbritannia, SO16 6YD
- Rekruttering
- Southampton General Hospital
-
Sutton, Storbritannia, SM2 5PT
- Rekruttering
- Royal Marsden Hospital
-
Torquay, Storbritannia, TQ2 7AA
- Rekruttering
- Torbay Hospital
-
Truro, Storbritannia, TR1 3LJ
- Rekruttering
- Royal Cornwall Hospital
-
-
-
-
-
Dresden, Tyskland, 01307
- Rekruttering
- Universitätsklinikum Carl Gustav Carus
-
Halle, Tyskland, 06120
- Rekruttering
- Universitätsklinikum Halle (Saale)
-
Hamburg, Tyskland, 22763
- Rekruttering
- Asklepios Klinik Altona
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
Are male adults (defined as ≥18 years of age or of an acceptable age according to local regulations at the time of giving informed consent).
-
Must have documented progressive prostate cancer based on at least one of the following criteria:
- Serum/plasma PSA progression, by local laboratory, defined as two consecutive increases in PSA over a previous reference value, each measured sequentially at least 1 week apart. The PSA value at screening is required to be ≥1.0 ng/mL.
- Radiographic soft tissue progression as per PCWG3-modified RECIST v1.1.
- Radiographic progression of bone disease: evaluable disease or new bone lesion(s) by bone scan per PCWG3 criteria.
-
Had previously received one or two prior androgen receptor pathway inhibitor treatments and experienced disease progression during or after a minimum of 8 weeks of therapy.
-
Must not have received systemic cytotoxic chemotherapy, including taxane-based chemotherapy, for mCRPC.
-
Must have had prior orchiectomy and/or have ongoing androgen-deprivation therapy and a castrate-level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L). Participant being treated with luteinizing hormone-releasing hormone agonists or antagonists must continue such treatment throughout the study.
-
Must have an Eastern Cooperative Oncology Group performance score of 0 or 1.
Key Exclusion Criteria:
- Have received prior treatment with B7-H3 targeted therapy, including B7-H3 ADCs.
- Have uncontrolled or significant cardiovascular disease, as defined in the protocol.
- Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or have current ILD/pneumonitis.
NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: BNT324
|
Intravenous infusion
Andre navn:
|
|
Aktiv komparator: Docetaxel pluss prednisolon/prednisolon
|
Intravenous infusion Oral |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
rPFS assessed by BICR
Tidsramme: From randomization to end of study, i.e., up to 58 months
|
By arm. rPFS is defined as time from randomization to radiographic disease progression per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
OS
Tidsramme: From randomization to end of study, i.e., up to 58 months
|
By arm. OS is defined as time from randomization to death from any cause. |
From randomization to end of study, i.e., up to 58 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to first subsequent therapy (TFTS)
Tidsramme: From randomization to end of study, i.e., up to 58 months
|
By arm. TFST is defined as time from randomization to initiation of the first subsequent systemic anticancer therapy or death, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Objective response rate (ORR)
Tidsramme: From randomization to end of study, i.e., up to 58 months
|
By arm. ORR is defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) (per PCWG3-modifed RECIST v1.1 as assessed by BICR) is observed as best overall response. |
From randomization to end of study, i.e., up to 58 months
|
|
Duration of response (DOR)
Tidsramme: From randomization to end of study, i.e., up to 58 months
|
By arm. DOR is defined as time from first objective response (confirmed CR or PR per PCWG3-modified RECIST v1.1 criteria as assessed by BICR) to first occurrence of objective tumor progression (progressive disease per PCWG3-modified RECIST v1.1 criteria as assessed by BICR) or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Time to pain progression (TTPP)
Tidsramme: From randomization to safety follow-up visit (30 days after the last dose), i.e., up to 58 months
|
By arm. TTPP is defined as time from randomization to pain progression as determined by Brief Pain Inventory-Short Form Item 3 "worst pain in 24 hours" and opiate analgesic use (Analgesic Quantification Algorithm score). |
From randomization to safety follow-up visit (30 days after the last dose), i.e., up to 58 months
|
|
rPFS as assessed by investigator
Tidsramme: From randomization to end of study, i.e., up to 58 months
|
By arm. rPFS is defined as time from randomization to radiographic disease progression per PCWG3-modified RECIST v1.1 criteria, or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Time to first symptomatic skeletal-related event (SSRE)
Tidsramme: From randomization to end of study, i.e., up to 58 months
|
By arm. Time to first SSRE is defined as time from randomization to first occurrence of any of the following SSREs:
|
From randomization to end of study, i.e., up to 58 months
|
|
Time to prostate-specific antigen (PSA) progression (by central lab testing results)
Tidsramme: From baseline to end of treatment visit, i.e., up to 58 months
|
By arm. Time to PSA progression is defined as time from randomization to PSA progression per PCWG3 criteria. |
From baseline to end of treatment visit, i.e., up to 58 months
|
|
PSA response (by central lab testing results)
Tidsramme: From baseline to end of treatment visit, i.e., up to 58 months
|
By arm. PSA response is defined as having a post-baseline PSA reduction ≥50% from baseline with a consecutive confirmation assessment at least 3 weeks later per PCWG3 criteria. |
From baseline to end of treatment visit, i.e., up to 58 months
|
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs
Tidsramme: From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
TEAEs by relationship and by arm. |
From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
|
Number and percentage of participants with dose interruptions, reductions or discontinuations of study treatment due to TEAEs
Tidsramme: From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
By arm. |
From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: BioNTech Responsible Person, BioNTech SE
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- BNT324-03
- 2025-524445-27-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .